Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Professor Udai Banerji will attened this conference.
Any chance of AVA6000 being mentioned?
https://www.convergencesciencecentre.ac.uk/news-events/events-calendar/evnets-archive/2024/01/17/default-calendar/convergence-science-centre-annual-symposium---engineering-cancer-research
Cheolwoong Lee
Head of BD at Alvogen Korea
20 hours
Impressive progress by AffyXell in cell and gene therapy! The synergy of DW-MSC and Affimer technology is exciting. Looking forward to the clinical outcomes of AFX001 and AFX002. Congratulations on the successful FDA meeting!
https://www.linkedin.com/mwlite/feed/update/activity:7148963212976111616
Seng-Ho Jeon 3rd degree or more
CEO & President of Daewoong pharmaceutical
1 day Edited
AffyXell is a clinical ready stage biotechnology company with a proprietary platform engine to develop novel cell and gene therapy (CGT). This platform is a powerhouse not only for internal pipelines but also for external collaboration. We recently signed a research collaboration agreement with one of the pioneering big pharmas in CGT, which is a testimonial of the potential strength and expandability of AffyXell’s platform technologies.
We are dedicated to developing off-the-shelf allogenic cell therapies for the treatment of transplantation rejection and immune disorders. Our technology enables the merge of two different platform technologies from our parent companies: Daewoong's Mesenchymal Stem Cell technology (DW-MSC) and Avacta's Affimer technology.
Our strategic approach is to genetically modify MSCs to express Affimers, with the aim of achieving three key objectives:
1) Significantly enhanced efficacy compared to conventional MSC therapeutics.
2) A clear understanding of the mechanism of action.
3) Consistent, reproducible, and cost-effective manufacturing.
Affimer proteins, based on Stefin A, serve as non-IgG scaffold proteins capable of acting as antagonists or agonists by binding to specific antigens, much like antibodies. We have established cell banks for both DW-MSC and AffyXell, enabling consistent, reproducible, and scalable batch production from a single cell bank.
Our lead pipeline candidate, AFX001, is designed to inhibit CD40-CD40L signaling by binding to CD40L and blocking the interaction through the secretion of an anti-CD40L antagonistic Affimer. CD40-CD40L signaling plays a pivotal role in T cell activation, T cell-mediated B cell activation/differentiation, and immune responses involving antigen-presenting cells (APCs). Inhibition of T cell and B cell activation through CD40-CD40L signaling suppression offers therapeutic potential for conditions like GvHD and various autoimmune diseases, including systemic lupus erythematosus, type 1 diabetes mellitus, multiple sclerosis, and rheumatoid arthritis.
Excitingly, we have demonstrated AFX001's outstanding efficacy compared to un-transduced MSCs using a humanized Graft versus Host Disease (GvHD) mouse model. Furthermore, AFX001 exhibits comparable efficacy to a pre-clinically verified anti-CD40L antibody.
We recently concluded a smooth pre-IND meeting with the US FDA, and we are on track to initiate patient-targeted clinical trials in the second half of next year. We are ready to manufacture GMP batch for the clinical trials with the established GMP-grade Master Cell Bank (MCB) and Working Cell Bank (WCB).
The second program, AFX002 is uniquely positioned to activate patients’ regulatory T cells to induce immune tolerance, which is a critical lacking mechanism in many autoimmune disease patients. We are in the final stage of lead cell selection, and we
Hi all, just wanted to take a minute to wish you all a very merry Christmas and a happy year, most of all good health! These days people don't spend much time or thought on some personal words to their friends and family, they just copy and paste some random stuff and send it on. So, after all we've been though together this year I want to thank you for your friendship and wish you a happy 2018! You are the best gymnastics group anyone could ask for. Best wishes, Susan
Billionaires Ken Griffin and David Geffen Give $400 Million to Fight Cancer
Gift is largest in Memorial Sloan Kettering’s 150-year history
https://www.bloomberg.com/news/articles/2023-12-12/billionaires-griffin-geffen-give-nyc-s-msk-cancer-center-400-million-gift
Https://www.thetimes.co.uk/article/avacta-reduces-side-effects-of-common-chemotherapy-27rc58qt9
Is this us?
https://www.cancertreatmentreviews.com/article/S0305-7372(23)00161-5/fulltext#%20
Hey guys just popped in to say hello
I filtered everyone a long time ago so I can clearly listen only to sujood.
He is feeding me some very accurate data from the 5th dimension … never been wrong. Amazing.
He made me so much dough I started putting out 50£ notes in a ball for guests instead of butterscotch.
Anyway, he sends you his love and he asked me to pass on this message:
“The white rabbit has grown a horn,
Don’t follow the one-legged man to the Belgian field”
He told me that Hursboot will understand it.
It could be interesting
https://youtu.be/OCEg4OSOsPs?feature=shared
Good article
+
Affimers were mentioned
https://www.abingdonhealth.com/lateral-flow-tests-past-present-future/